Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple enzyme supplement calm essential tremors?

NCT ID NCT07238725

Symptom relief Sponsor: Pico Entech Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a dietary supplement containing aldehyde dehydrogenase (ALDH) enzyme can ease tremors in people with essential tremor. Forty adults will take the supplement twice daily for three months. Researchers will measure changes in tremor severity and daily function using standard rating scales.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aldehyde dehydrogenase (ALDH) enzyme dietary supplement
What this could lead to
If it works, this could point toward a simple dietary supplement to help reduce tremor severity and improve daily activities for people with essential tremor.
What could go wrong
This is a very early, small study with only 40 participants and no placebo group, so results may not be reliable or generalizable. The supplement may have no real effect on tremors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥ 19 years who provide written informed consent. * Diagnosed with Essential Tremor (ET) by a board-certified neurologist or neurosurgeon. * Presence of postural or intention tremor in the dominant hand/arm with a CRST score ≥ 2. * Stable medication regimen for at least 30 days prior to enrollment. * No structural brain abnormalities on MRI within the last 3 years. * Eligible according to investigator assessment and agreement by two clinical team members. Exclusion Criteria: * Presence of secondary tremor causes (e.g., Parkinsonism, dystonia). * Significant medical conditions such as severe arrhythmia, renal failure, hepatic failure, acute stroke, or epilepsy. * Contraindications to MRI (e.g., pacemakers, metal implants).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential tremor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential tremor Tremor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential tremor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.